JP7652434B2 - がん治療のためのビアミノキノリンとナノ製剤 - Google Patents

がん治療のためのビアミノキノリンとナノ製剤 Download PDF

Info

Publication number
JP7652434B2
JP7652434B2 JP2022517438A JP2022517438A JP7652434B2 JP 7652434 B2 JP7652434 B2 JP 7652434B2 JP 2022517438 A JP2022517438 A JP 2022517438A JP 2022517438 A JP2022517438 A JP 2022517438A JP 7652434 B2 JP7652434 B2 JP 7652434B2
Authority
JP
Japan
Prior art keywords
inhibitors
cancer
nps
baq
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022517438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549169A (ja
JPWO2021055705A5 (enExample
Inventor
リー ユアンペイ
マー チャオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022549169A publication Critical patent/JP2022549169A/ja
Publication of JPWO2021055705A5 publication Critical patent/JPWO2021055705A5/ja
Priority to JP2025036781A priority Critical patent/JP2025094953A/ja
Application granted granted Critical
Publication of JP7652434B2 publication Critical patent/JP7652434B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/481—Diagnostic techniques involving the use of contrast agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2022517438A 2019-09-18 2020-09-18 がん治療のためのビアミノキノリンとナノ製剤 Active JP7652434B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025036781A JP2025094953A (ja) 2019-09-18 2025-03-07 がん治療のためのビアミノキノリンとナノ製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902156P 2019-09-18 2019-09-18
US62/902,156 2019-09-18
PCT/US2020/051430 WO2021055705A1 (en) 2019-09-18 2020-09-18 Biaminoquinolines and nanoformulations for cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025036781A Division JP2025094953A (ja) 2019-09-18 2025-03-07 がん治療のためのビアミノキノリンとナノ製剤

Publications (3)

Publication Number Publication Date
JP2022549169A JP2022549169A (ja) 2022-11-24
JPWO2021055705A5 JPWO2021055705A5 (enExample) 2023-09-25
JP7652434B2 true JP7652434B2 (ja) 2025-03-27

Family

ID=74884705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517438A Active JP7652434B2 (ja) 2019-09-18 2020-09-18 がん治療のためのビアミノキノリンとナノ製剤
JP2025036781A Pending JP2025094953A (ja) 2019-09-18 2025-03-07 がん治療のためのビアミノキノリンとナノ製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025036781A Pending JP2025094953A (ja) 2019-09-18 2025-03-07 がん治療のためのビアミノキノリンとナノ製剤

Country Status (6)

Country Link
US (1) US20230348419A1 (enExample)
EP (1) EP4031543A4 (enExample)
JP (2) JP7652434B2 (enExample)
CN (2) CN115023418B (enExample)
CA (1) CA3154678A1 (enExample)
WO (1) WO2021055705A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566666A (zh) 2018-05-14 2021-03-26 努瓦申生物公司 靶向抗癌核激素受体的化合物
AU2020274113A1 (en) 2019-05-14 2021-11-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
CA3218577A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114948938B (zh) * 2022-02-22 2023-08-11 江苏省中医院 白术内酯i在制备预防和/或治疗宫颈癌的药物中的用途
CN114948901B (zh) * 2022-05-06 2023-04-21 郑州大学第一附属医院 一种协同治疗乳腺癌的依西美坦纳米粒、制剂及其制备方法
CN116059172B (zh) * 2023-02-01 2025-05-13 中山大学附属第八医院（深圳福田） 一种纳米递药系统及其制备方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513101A (ja) 2011-04-29 2014-05-29 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規のビスアミノキノリン化合物、それから調製した医薬組成物、及びそれらの使用
WO2016196393A2 (en) 2015-05-29 2016-12-08 Presage Biosciences, Inc. Autophagy-inhibiting compounds and uses thereof
US20170275252A1 (en) 2014-08-08 2017-09-28 The Trustees Of The University Of Pennsylvania Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
US20180111904A1 (en) 2015-04-17 2018-04-26 The Trustees Of The University Of Pennsylvania Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
US20180280372A1 (en) 2016-11-22 2018-10-04 Washington University Compositions and methods for inhibiting autophagy and contraception

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004229404B2 (en) * 2003-04-11 2008-01-10 Taigen Biotechnology Aminoquinoline compounds
EP2547367A4 (en) * 2010-03-16 2016-02-24 Ge Healthcare Bio Sciences Ab SYSTEM FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS
WO2015068142A2 (en) * 2013-11-11 2015-05-14 Cellworks Group, Inc. Compositions, process of preparation of said compositions, uses and method of management of myeloproliferative disorder

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513101A (ja) 2011-04-29 2014-05-29 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規のビスアミノキノリン化合物、それから調製した医薬組成物、及びそれらの使用
US20170275252A1 (en) 2014-08-08 2017-09-28 The Trustees Of The University Of Pennsylvania Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
US20180111904A1 (en) 2015-04-17 2018-04-26 The Trustees Of The University Of Pennsylvania Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
WO2016196393A2 (en) 2015-05-29 2016-12-08 Presage Biosciences, Inc. Autophagy-inhibiting compounds and uses thereof
US20180280372A1 (en) 2016-11-22 2018-10-04 Washington University Compositions and methods for inhibiting autophagy and contraception

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
David I. Fletcher; et al.，Synthesis and pharmacological testing of polyaminoquinolines as blockers of the apamin-sensitive Ca2+-activated K+ channel (SKCa)，Bioorganic & Medicinal Chemistry，2007年，15 (16)，5457-5479
Ma, Zhao; et al，Pharmacophore hybridisation and nanoscale assembly to discover self-delivering lysosomotropic new-chemical entities for cancer therapy，Nature Communications ，2020年09月15日，11，4615, 1-12

Also Published As

Publication number Publication date
JP2022549169A (ja) 2022-11-24
EP4031543A4 (en) 2023-09-27
CN119591543A (zh) 2025-03-11
JP2025094953A (ja) 2025-06-25
EP4031543A1 (en) 2022-07-27
US20230348419A1 (en) 2023-11-02
CN115023418B (zh) 2024-11-19
CA3154678A1 (en) 2021-03-25
CN115023418A (zh) 2022-09-06
WO2021055705A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
JP7652434B2 (ja) がん治療のためのビアミノキノリンとナノ製剤
US20250049945A1 (en) Method of treatment for solid tumors containing hypoxia and/or stroma features
CN112239209B (zh) 通过孔改性的介孔二氧化硅纳米颗粒进行的药物递送
UA123889C2 (uk) Кон'югати піролобензодіазепін-антитіло
CN112334127A (zh) 生物响应水凝胶基质及使用方法
CA3195153A1 (en) Folate receptor targeted nanoparticle drug conjugates and uses thereof
KR102179530B1 (ko) 광감작제를 포함하는 자기 조립 나노입자 및 이를 포함하는 광역학 치료용 조성물
CN116848094B (zh) 叔胺类脂质化合物及其应用
CN111973556B (zh) 载小分子药聚合物囊泡及其制备方法与应用
KR20220100904A (ko) 암의 치료에 유용한 ido 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
US11191745B2 (en) Silica nanoparticle with an insoluble drug
US20250241886A1 (en) Drug-loaded mesoporous silica nanoparticle for prevention and treatment of brain cancers or brain metastases
JP2024534479A (ja) 非晶質光増感性粒子、その調製方法、及びその使用方法
KR20230033075A (ko) 초음파 감응성 폴리머좀 및 이의 제조방법
AU2018202949B2 (en) Bolaamphiphilic compounds, compositions and uses thereof
KR20240000677A (ko) 나노-바이오 구조 조절을 기반으로 하는 새로운 고리형 펩티드, 이를 포함하는 코어/쉘 구조의 펩티좀 및 이의 용도
AU2019249628B2 (en) Bladder cancer photodynamic therapeutic agents with off-on magnetic resonance imaging enhancement
AU2020329923A1 (en) Palm for the treatment of Chemotherapy-Induced Peripheral Neuropathy incidental to the treatment of cancer
US20250269031A1 (en) Mitochondria targeting quinolinium-drug conjugates and their self-assembling nanoformulations for cancer therapy
Wang et al. Bench-to-bedside translation of podophyllotoxin-based nanomedicines for cancer treatment: Utopias and reality?
Quiñonero Muñoz et al. Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer
CN119101011A (zh) pH响应性叔胺类脂质化合物及其应用
CN119497732A (zh) 基于序列固定聚赖氨酸的pH敏感膜裂解材料及其应用
HK1190718A (en) Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250307

R150 Certificate of patent or registration of utility model

Ref document number: 7652434

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150